Patent ID: 8278038

Claim:
A method for determining a cancer therapy regimen for treating myeloma in a patient comprising: a) measuring the level of expression of at least one nucleic acid sequence selected from the group consisting of sequences recognized by probesets of predictive markers numbered 1-547 in Table 1A, 658-871 in Table 1B and 873-876 in Table 1B in a patient sample comprising tumor cells, wherein the sequences recognized by probesets of the predictive markers: i) numbered 1-547 consist of SEQ ID NOs: 1-513, ii) numbered 658-871 and 873-876 consist of SEQ ID NOs:614-830; b) comparing the level of expression of the at least one nucleic acid sequence to a reference expression level of that sequence to determine whether the level of expression of the at least one nucleic acid sequence is upregulated in the patient sample comprising tumor cells; and c) determining a cancer therapy regimen for treating myeloma based on the expression level of the predictive marker or markers, wherein the cancer therapy regimen is proteasome inhibition-based therapy, wherein i) upregulation of at least one nucleic acid sequence selected from the group consisting of sequences recognized by probesets of predictive markers numbered 1-547 indicates nonresponsiveness to proteasome inhibition therapy and the patient would not benefit from this cancer therapy regimen; and ii) upregulation of at least one nucleic acid sequence selected from the group consisting of sequences recognized by probesets of predictive markers numbered 658-871 and 873-876 indicates responsiveness to proteasome inhibition therapy and the patient would benefit from this cancer therapy regimen.